Publications by authors named "Catrin Heim"
Treatment resistance and immune escape are hallmarks of metastatic rhabdomyosarcoma (RMS), underscoring the urgent medical need for therapeutic agents against this disease entity as a key challenge in pediatric oncology. Chimeric antigen receptor (CAR)-based immunotherapies, such as the ErbB2 (Her2)-CAR-engineered natural killer (NK) cell line NK-92/5.28.
View Article and Find Full Text PDFIntroduction: Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR) technology to natural killer (NK) cells may offer safe, effective, and affordable therapies that enhance cancer immune surveillance.
Methods: Here, we assess the efficacy of clinically usable CAR-engineered NK cell line NK-92/5.
The dismal prognosis of pediatric and young adult patients with high-risk rhabdomyosarcoma (RMS) underscores the need for novel treatment options for this patient group. In previous studies, the tumor-associated surface antigen ERBB2 (HER2/neu) was identified as targetable in high-risk RMS. As a proof of concept, in this study, a novel treatment approach against RMS tumors using a genetically modified natural killer (NK)-92 cell line (NK-92/5.
View Article and Find Full Text PDFArticle Synopsis
- The use of chimeric antigen receptor (CAR) T cells has shown promise in treating some blood cancers, but solid tumors like RMS are more difficult to treat due to lower quality T cells; therefore, the study proposes using CAR-modified cytokine-induced killer (CIK) cells, which combine properties of T cells and natural killer (NK) cells.
- In experiments with mice, ERBB2-CAR CIK cells effectively prevented RMS tumor growth in all treated cases, highlighting their potential to enhance anti-tumor immunity,